MA47509A - Traitement par anticorps anti-pd-l1 du cancer de la vessie - Google Patents

Traitement par anticorps anti-pd-l1 du cancer de la vessie

Info

Publication number
MA47509A
MA47509A MA047509A MA47509A MA47509A MA 47509 A MA47509 A MA 47509A MA 047509 A MA047509 A MA 047509A MA 47509 A MA47509 A MA 47509A MA 47509 A MA47509 A MA 47509A
Authority
MA
Morocco
Prior art keywords
bladder cancer
antibody treatment
antibody
treatment
bladder
Prior art date
Application number
MA047509A
Other languages
English (en)
Inventor
yong Ben
John Andrew Blake-Haskins
Mohammed Dar
Ashok Gupta
Tony Ho
Robert Iannone
Xiaoping Jin
John Kurland
Shannon Morris
Marlon Rebelatto
Li Shi
Jill Walker
Magdalena Zajac
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of MA47509A publication Critical patent/MA47509A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G01N33/542—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase with steric inhibition or signal modification, e.g. fluorescent quenching
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • General Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA047509A 2017-02-16 2018-02-16 Traitement par anticorps anti-pd-l1 du cancer de la vessie MA47509A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762459700P 2017-02-16 2017-02-16

Publications (1)

Publication Number Publication Date
MA47509A true MA47509A (fr) 2019-12-25

Family

ID=63169615

Family Applications (1)

Application Number Title Priority Date Filing Date
MA047509A MA47509A (fr) 2017-02-16 2018-02-16 Traitement par anticorps anti-pd-l1 du cancer de la vessie

Country Status (12)

Country Link
US (2) US20190359715A1 (fr)
EP (1) EP3582805A4 (fr)
JP (2) JP2020507596A (fr)
KR (3) KR20230145547A (fr)
CN (2) CN110290803A (fr)
AU (2) AU2018221822A1 (fr)
CA (1) CA3052652A1 (fr)
EA (1) EA201991870A1 (fr)
IL (3) IL320916A (fr)
MA (1) MA47509A (fr)
SG (1) SG11201907211TA (fr)
WO (1) WO2018152415A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
LT3142751T (lt) * 2014-05-13 2019-09-25 Medimmune Limited Anti-b7-h1 ir anti-ctla-4 antikūnai nesmulkialąstelinio plaučių vėžio gydymui
MA47509A (fr) * 2017-02-16 2019-12-25 Medimmune Llc Traitement par anticorps anti-pd-l1 du cancer de la vessie
CN110914302A (zh) 2017-06-01 2020-03-24 赛托姆克斯治疗学股份有限公司 可活化抗pdl1抗体及其使用方法
JP2023526400A (ja) * 2020-05-21 2023-06-21 アストラゼネカ・アクチエボラーグ 局所進行性又は転移性尿路上皮がんにおける免疫療法に対する感受性に関連する遺伝子変異量
WO2026003724A1 (fr) * 2024-06-25 2026-01-02 Astrazeneca Ab Polythérapie comprenant du durvalumab et du cisplatine/gemcitabine destinée à être utilisée dans le traitement du cancer de la vessie

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7947261B2 (en) * 2003-05-23 2011-05-24 Nektar Therapeutics Conjugates formed from polymer derivatives having particular atom arrangements
LT3142751T (lt) * 2014-05-13 2019-09-25 Medimmune Limited Anti-b7-h1 ir anti-ctla-4 antikūnai nesmulkialąstelinio plaučių vėžio gydymui
KR20170132171A (ko) * 2015-02-26 2017-12-01 메르크 파텐트 게엠베하 암 치료를 위한 ｐｄ­１ ／ ｐｄ­ｌ１ 저해제
EP3303632B2 (fr) * 2015-05-29 2023-05-10 F. Hoffmann-La Roche AG Méthodes diagnostiques et thérapeutiques pour le cancer
EP3387155A4 (fr) * 2015-12-10 2019-06-12 Definiens AG Procédés de traitement et de sélection de patients sensibles à l'immunothérapie anticancéreuse
JP2019514889A (ja) * 2016-04-25 2019-06-06 メディミューン，エルエルシー 抗ｐｄ−ｌ１および抗ｃｔｌａ−４抗体の共製剤を含む組成物
MA47509A (fr) * 2017-02-16 2019-12-25 Medimmune Llc Traitement par anticorps anti-pd-l1 du cancer de la vessie

Also Published As

Publication number Publication date
IL268460A (en) 2019-09-26
KR20250025517A (ko) 2025-02-21
CA3052652A1 (fr) 2018-08-23
SG11201907211TA (en) 2019-09-27
IL302777A (en) 2023-07-01
JP2024038034A (ja) 2024-03-19
US20220332828A1 (en) 2022-10-20
IL320916A (en) 2025-07-01
EP3582805A4 (fr) 2021-03-10
CN118001389A (zh) 2024-05-10
EP3582805A1 (fr) 2019-12-25
AU2025201227A1 (en) 2025-03-13
AU2018221822A1 (en) 2019-09-26
KR20230145547A (ko) 2023-10-17
JP2020507596A (ja) 2020-03-12
KR20190117014A (ko) 2019-10-15
EA201991870A1 (ru) 2020-02-12
WO2018152415A1 (fr) 2018-08-23
US20190359715A1 (en) 2019-11-28
CN110290803A (zh) 2019-09-27

Similar Documents

Publication Publication Date Title
EP3341413A4 (fr) Traitement ciblé par anticorps monoclonal anti-despr et imagerie pour cancer et avc
MA47604A (fr) Anticorps anti-pd-1 pour le traitement du cancer du poumon
MA47501A (fr) Dérivé de di-nucléotides cycliques pour le traitement du cancer
IL262892A (en) Anti pd-1 and anti-lag3 antibodies for cancer treatment
EP3494142A4 (fr) Anticorps anti-siglec-7 pour le traitement du cancer
MA47208A (fr) Procédés de traitement du cancer à l'aide d'anticorps anti-pd-1
MA43746A (fr) Dérivés de 2-cyanoisoindoline pour le traitement du cancer
EP3532489A4 (fr) Anticorps monoclonaux neutralisants anti-tl1a
EP3441086A4 (fr) Anticorps monoclonal anti-pd-1
PL4339615T3 (pl) Przeciwciała anty-pd-1 do stosowania w leczeniu raka
EP3752180A4 (fr) Méthodes de traitement du cancer avec des anticorps anti-pd-1
EP3621592A4 (fr) Polythérapies pour le traitement du cancer
MA50943A (fr) Anticorps anti-liv1 humanisés pour le traitement du cancer du sein
MA50409A (fr) Polythérapies pour le traitement du cancer
IL284875A (en) Lasofoxifene treatment of breast cancer
MA47408A (fr) Traitement du cancer
EP3820461A4 (fr) Méthode de traitement du cancer
EP3610026A4 (fr) Méthodes de traitement du cancer de la vessie
IL284807A (en) Antibodies specific to human nectin-2
MA46361A (fr) Traitement du cancer de la prostate
MA52627A (fr) Traitement du cancer
PL3679069T3 (pl) Przeciwciała przydatne w diagnostyce nowotworów
EP3733175A4 (fr) Traitement du cancer
IL281845A (en) Combination therapy for the treatment of cancer
EP3652195A4 (fr) Conjugué de saporine peptidique pour le traitement du cancer